AstraZeneca has committed USD 2 billion to Summit Therapeutics in a partnership that includes testing their oncology therapies in combination. The arrangement focuses on Summit’s ivonescimab, a treatment currently undergoing evaluation by the US Food and Drug Administration for a specific type of lung cancer.
Following Monday’s announcement on September 28, Summit’s shares climbed upwards of 15% in extended trading.
AstraZeneca to Buy Convertible Shares in Summit
Under the transaction, AstraZeneca will purchase newly issued preferred shares that are convertible into Summit Therapeutics common stock. This investment prices the shares at USD 18.36 per common share, exceeding Summit’s closing price of USD 15.48 on Monday. Subject to customary conditions, Summit anticipates the acquisition will finalize by the end of the week.
Upon completion, AstraZeneca will possess rights corresponding to approximately 12% of Summit’s outstanding common stock, or roughly 10.6% when factoring in shares that may be issued at a later date. Regulatory approvals are necessary before the preferred shares can be converted into common stock. The equity investment and the collaborative clinical efforts operate as distinct components of the accord.
Summit intends to direct the capital toward the ongoing development of ivonescimab. The therapy was originally developed by Akeso, a Chinese pharmaceutical company, with Summit maintaining the rights to commercialize and develop it across several markets outside of China. While the drug has received approval for certain lung cancer patients within China, it is still considered an experimental medication in the United States and Europe.
Companies Plan Cancer Drug Combination Trials
Summit and AstraZeneca have entered into a clinical trial partnership to examine ivonescimab in tandem with AstraZeneca’s sonesitatug vedotin, starting with gastrointestinal cancers. Each company will provide its proprietary medication, split the expenses of the trials, and retain the commercial and development rights to its respective product.
Ivonescimab is designed to bind to two distinct proteins: PD-1, which assists cancer cells in evading immune system detection, and VEGF, which aids tumors in developing blood vessels. Sonesitatug vedotin functions as an antibody-drug conjugate, engineered to deliver a targeted cancer-killing agent directly to specific cells. The upcoming studies will evaluate the efficacy and performance of administering both therapies simultaneously.
Additionally, the firms established a non-binding preliminary understanding to investigate future trials combining ivonescimab with other oncology treatments from AstraZeneca. This expanded clinical initiative depends on negotiating a subsequent agreement. Summit noted that the current arrangement involves no extra financial obligations related to milestones, royalties, revenues, or profits.
FDA Review of Ivonescimab Continues
In an unrelated regulatory matter, the FDA is evaluating Summit’s submission to pair ivonescimab with chemotherapy for patients diagnosed with a particular form of advanced non-small-cell lung cancer. This patient group carries an EGFR gene mutation and has undergone prior targeted therapy. Summit’s timeline indicates November 14, 2026, as the goal date for the FDA’s ruling.
The current FDA evaluation is specific to ivonescimab combined with chemotherapy and is separate from the novel combination trials planned with AstraZeneca. The gastrointestinal cancer studies unveiled on Monday have not yet commenced; these investigations will generate data regarding the safety and effectiveness of the combination in trial participants. In the interim, Summit Therapeutics maintains its broader research program for ivonescimab across various cancer indications.
Also Read: AI and Palliative Care: Is This a New Era in Blood Cancer Therapy?
